Cargando…

A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma

BACKGROUND: Preclinical data suggest some cannabinoids may exert antitumour effects against glioblastoma (GBM). Safety and preliminary efficacy of nabiximols oromucosal cannabinoid spray plus dose-intense temozolomide (DIT) was evaluated in patients with first recurrence of GBM. METHODS: Part 1 was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Twelves, Chris, Sabel, Michael, Checketts, Daniel, Miller, Sharon, Tayo, Bola, Jove, Maria, Brazil, Lucy, Short, Susan C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039032/ https://www.ncbi.nlm.nih.gov/pubmed/33623076 http://dx.doi.org/10.1038/s41416-021-01259-3

Ejemplares similares

Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
por: D’hooghe, Marie, et al.
Publicado: (2021)

A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
por: Überall, Michael A
Publicado: (2020)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex(®) (THC:CBD, nabiximols) oromucosal spray
por: Etges, Tilden, et al.
Publicado: (2016)

Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2022)

Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2021)

Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX(®)) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials
por: Turri, Mara, et al.
Publicado: (2018)

Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis
por: Birke, Rüdiger, et al.
Publicado: (2022)

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis‐related spasticity
por: Celius, Elisabeth G., et al.
Publicado: (2018)

Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray
por: Schwittay, Maximilian A., et al.
Publicado: (2021)

Oromucosal Administration of Interferon to Humans
por: Beilharz, Manfred W., et al.
Publicado: (2010)

Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol
por: Bhardwaj, Anjali K., et al.
Publicado: (2018)

Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings
por: Flachenecker, Peter, et al.
Publicado: (2018)

A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity
por: Marinelli, Lucio, et al.
Publicado: (2017)

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
por: Akgün, Katja, et al.
Publicado: (2019)

Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity
por: Gajofatto, Alberto, et al.
Publicado: (2023)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Oromucosal Alginate Films with Zein Nanoparticles as a Novel Delivery System for Digoxin
por: Rodrigues, Daniela A., et al.
Publicado: (2021)

Oromucosal immunomodulation as clinical spectrum mitigating factor in SARS‐CoV‐2 infection
por: Rodríguez‐Argente, Francisco, et al.
Publicado: (2020)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder
por: Mills, Llewellyn, et al.
Publicado: (2022)

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers
por: Stott, Colin, et al.
Publicado: (2013)

Nabiximols effect on blood pressure and heart rate in post-stroke patients of a randomized controlled study
por: Rosa, Gian Marco, et al.
Publicado: (2022)

Evaluation of repeated dosing of a dexmedetomidine oromucosal gel for treatment of noise aversion in dogs over a series of noise events
por: Gruen, Margaret, et al.
Publicado: (2020)

Psychosocial Characteristics of Oromucosal Diseases in Psychiatric Patients: Observational Study from Indian Dental College
por: Suresh, K V, et al.
Publicado: (2014)

Use of Detomidine Oromucosal Gel for Alleviation of Acute Anxiety and Fear in Horses: A Pilot Study
por: Dai, Francesca, et al.
Publicado: (2020)

Prevalence of oromucosal lesions in HIV positive patients receiving haart-A prospective clinical study
por: Maloth, Saritha, et al.
Publicado: (2020)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
por: Lim, Michael, et al.
Publicado: (2022)

Comparative evaluation of rapidity of action of benzydamine hydrochloride 0.3% oromucosal spray and benzydamine hydrochloride 3 mg lozenges in patients with acute sore throat: A phase IV randomized trial
por: Valerio, Carmelina, et al.
Publicado: (2023)

The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders
por: Jakubovski, Ewgeni, et al.
Publicado: (2020)

Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma
por: Ward, Sarah M., et al.
Publicado: (2018)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
por: Herbener, Verena J., et al.
Publicado: (2020)

Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma
por: Kim, Hyungsin, et al.
Publicado: (2019)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qoikqq07f4dl6j88h4ol95dcc5